Development of natural immunity to Neisseria meningitidis

Vaccine

Volumn 19, Issue 11-12, 2001, Pages 1327-1346

  Pollard, Andrew J ^a   Frasch, Carl ^b  

^a BC CHILDREN S HOSPITAL   (Canada)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

Epidemic potential; Nasopharyngeal; Neisseria meningitidis

Indexed keywords

BACTERIAL ANTIGEN; BACTERIUM ANTIBODY; MENINGOCOCCUS VACCINE;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY SPECIFICITY; BACTERIAL IMMUNITY; CELLULAR IMMUNITY; COMPLEMENT ACTIVATION; DEVELOPED COUNTRY; EPIDEMIC; HUMAN; IMMUNOREACTIVITY; INDUSTRIALIZATION; MENINGOCOCCOSIS; MORTALITY; MUCOSAL IMMUNITY; NASOPHARYNX; NEISSERIA MENINGITIDIS; OPSONIZATION; PHAGOCYTOSIS; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; REVIEW; VACCINATION;

ANTIBODIES, BACTERIAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, BACTERIAL; CHILD, PRESCHOOL; COMPLEMENT ACTIVATION; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, MUCOSAL; IMMUNITY, NATURAL; INFANT; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NASOPHARYNX; NEISSERIA MENINGITIDIS; PHAGOCYTOSIS; POLYSACCHARIDES, BACTERIAL; SEROTYPING;

EID: 0035825093     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00333-9     Document Type: Review

References (249)

1. Carriage of Neisseria meningitidis and Neisseria lactamica in infants and children
2. Epidemiology and prevention of meningococcal disease
3. The changing epidemiology of meningococcal disease in the United States, 1992-1996
4. Meningococcal disease - New England 1993-1998
5. Epidemic serogroup B meningococcal disease in Oregon: The evolving epidemiology of the ET-5 strain
6. Vaccination programme for group C meningococcal infection is launched
7. Human immunity to the meningococcus. I. The role of humoral antibodies
8. Human immunity to the meningococcus. II. Development of natural immunity
9. Meningococcal disease falls in vaccine recipients
10. Preclinical studies on a group Y meningococcal conjugate vaccine
11. The relation of the meningococcidal activity of the blood to resistance to virulent meningococci
12. A study of the virulence of meningococci for man and of human susceptibility to meningococcic infection
13. Naturally occurring antibodies to Neisseria meningitidis
14. Meningococcal phenotypic and genotypic characteristics and human antibody levels
15. Cross-reactive antigens and immunity to diseases caused by encapsulated bacteria
16. Structural studies of the Escherichia coli K93 and K53 capsular polysaccharides
17. Serum bactericidal activity in a secondary school population following an outbreak of meningococcal disease: Effects of carriage and secretor status
18. Meningococcemia caused by serogroup W135. Association with hypogammaglobulinemia
19. Gamma-M deficiency predisposing to meningococcal septicaemia
20. Bactericidal activity of meningococcal antisera. Blocking by IgA of lytic antibody in human convalescent sera
21. Immunoepidemiology of meningococcal disease in military recruits. II. Blocking of serum bactericidal activity by circulating IgA early in the course of invasive disease
22. IgA blocks IgM and IgG-initiated immune lysis by separate molecular mechanisms
23. Risk of group A meningococcal disease: Bacterial interference and cross-reactive bacteria among mucosal flora
24. Epidemic meningococcal disease: Synthesis of a hypothetical immunoepidemiologic model
25. Factors influencing susceptibility to meningococcal disease during an epidemic in The Gambia, West Africa
26. Antigenic specificity of bactericidal antibodies in antisera to Neisseria meningitidis
27. Class-specific human bactericidal antibodies to capsular and noncapsular surface antigens of Neisseria meningitidis
28. Serum therapy of meningitis
29. A second controlled field trial of a serogroup A meningococcal polysaccharide vaccine in Alexandria
30. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age
31. Immunologic response of man to group B meningococcal polysaccharide vaccines
32. Serologic response to serogroup C meningococcal vaccine in Brazilian preschool children
33. Efficacy of meningococcal vaccine and barriers to vaccination
34. Successful intervention in a group A meningococcal outbreak in Auckland, New Zealand
35. Protective efficacy of a bivalent (A + C) meningococcal vaccine during a cerebrospinal meningitis epidemic in Rwanda
36. Analysis of meningococcal serogroup C-specific antibody levels in British Columbian children and adolescents
37. Control of meningococcal disease: Guidance for consultants in communicable disease control
38. Meningococcal vaccines. Current status and future possibilities
39. Control of meningococcal infection in the African meningitis belt by selective vaccination
40. Recent knowledge of the incidence and control of cerebrospinal fever
41. Physicochemical and immunological characterization of meningococcal group A polysaccharide-tetanus toxoid conjugates prepared by two methods
42. Immunological evaluation of meningococcal group C polysaccharide-tetanus toxoid conjugate in mice
43. Immunochemistry of groups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates
44. Development and phase I clinical testing of a conjugate vaccine against meningococcus A and C
45. An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues
46. Measurement of antibodies to meningococcal group B polysaccharide: Low avidity binding and equilibrium binding constants
47. Antibody responses to the capsular polysaccharide of Neisseria meningitidis serogroup B in patients with meningococcal disease
48. Complex of meningococcal group B polysaccharide and type 2 outer membrane protein immunogenic in man
49. Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide
50. Immune response of infants and children to disseminated infections with Neisseria meningitidis
51. The immune response to the capsular polysaccharide of Neisseria meningitidis Group B
52. The binding of activated C3 to polysaccharides and immunoglobulins
53. Preclinical evaluation of a novel group B meningococcal conjugate vaccine that elicits bactericidal activity in both mice and nonhuman primates
54. Bactericidal antibody responses of juvenile rhesus monkeys immunized with group B Neisseria meningitidis capsular polysaccharide-protein conjugate vaccines
55. Preclinical evaluation of group B Neisseria meningitidis and Escherichia coli K92 capsular polysaccharide-protein conjugate vaccines in juvenile rhesus monkeys
56. Dynamics of carriage of Neisseria meningitidis in a group of military recruits: Subtype stability and specificity of the immune response following colonization
57. Cross-reactivity of Neisseria gonorrhoeae and Neisseria meningitidis and the nature of antigens involved in the bactericidal reaction
58. Serum antibodies to cross-reactive Neisseria outer membrane antigens in healthy persons and patients with meningococcal disease
59. Immunogenicity of meningococcal antigens as detected in patient sera
60. Human immune response to meningococcal outer membrane protein epitopes after natural infection or vaccination
61. Vaccines for prevention of meningococcal disease
62. Meningococcal vaccines: Past present and future
63. New and impoved vaccines against meningococcal disease
64. Vaccine against group B Neisseria meningitidis: Protection trial and mass vaccination results in Cuba
65. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway
66. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: A randomized controlled trial in Chile
67. Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: Comparison with efficacy
68. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58
69. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing
70. Antibodies to meningococcal class 1 outer-membrane protein and its variable regions in patients with systemic meningococcal disease
71. Humoral immune response to class 1 outer membrane protein during the course of meningococcal disease
72. Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine
73. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine
74. Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins
75. Meningococcal PorA class 1 proteins exist in nature as a heterotrimeric porin with PorB proteins
76. Role of protein serotype antigens in protection against disease due to Neisseria meningitidis
77. Humoral immune response to the class 3 outer membrane protein during the course of meningococcal disease
78. Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial
79. Purification and characterization of eight class 5 outer membrane protein variants from a clone of Neisseria meningitidis serogroup A
80. Human immune response to epitopes on the meningococcal outer membrane class 5 protein following natural infection
81. The 5C protein of Neisseria meningitidis is highly immunogenic in humans and induces bactericidal antibodies
82. Human monoclonal antibodies against an epitope on the class 5c outer membrane protein common to many pathogenic strains of Neisseria meningitidis
83. Neisseria meningitidis producing the Opc adhesin binds epithelial cell proteoglycan receptors
84. Variable expression of the Opc outer membrane protein in Neisseria meningitidis is caused by size variation of a promoter containing poly-cytidine
85. The immune response of children to meningococcal lipooligosaccharides during disseminated disease is directed primarily against two monoclonal antibody-defined epitopes
86. The lipooligosaccharide immunotype as a virulence determinant in Neisseria meningitidis
87. Invasive isolates of Neisseria meningitidis possess enhanced immunoglobulin A1 protease activity compared to colonizing strains
88. Comparative analysis of immunoglobulin A1 protease activity among bacteria representing different genera, species, and strains
89. Human IgA1 blockade of IgG-initiated lysis of Neisseria meningitidis is a function of antigen-binding fragment binding to the polysaccharide capsule
90. The Neisseria type 2 IgA1 protease cleaves LAMP1 and promotes survival of bacteria within epithelial cells
91. Antibodies against IgA1 protease are stimulated both by clinical disease and asymptomatic carriage of serogroup A Neisseria meningitidis
92. Immunogenicity and evolutionary variability of epitopes within IgA1 protease from serogroup A Neisseria meningitidis
93. Persistence of antibodies to meningococcal IgA1 protease versus decay of antibodies to group A polysaccharide and Opc protein
94. Antigenic and molecular conservation of the gonococcal NspA protein
95. Detection of anti-NspA antibodies in sera from pateints convalescent after meningococcal infection
96. Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection
97. Implications of strain differences in surface expression of Neisseria surface protein A (NspA) for meningococcal B vaccine development
98. Immune responses in humans and animals to meningococcal transferrin-binding proteins: Implications for vaccine design
99. Human antibody response to meningococcal transferrin binding proteins: Evidence for vaccine potential
100. Human opsonins induced during meningococcal disease recognize outer membrane proteins PorA and PorB
101. Transferrin-binding proteins isolated from Neisseria meningitidis elicit protective and bactericidal antibodies in laboratory animals
102. The meningococcal transferrin-binding proteins 1 and 2 are both surface exposed and generate bactericidal antibodies capable of killing homologous and heterologous strains
103. Blocking of iron uptake from transferrin by antibodies against the transferrin binding proteins in Neisseria meningitidis
104. Transferrin receptors of Neisseria meningitidis: Promising candidates for a broadly cross-protective vaccine
105. Evaluation of recombinant transferrin-binding protein B variants from Neisseria meningitidis for their ability to induce cross-reactive and bactericidal antibodies against a genetically diverse collection of serogroup B strains
106. Safety and immunogenicity of a Neisseria meningitidis group B transferrin binding protein vaccine in adults
107. Neisserial antigen H.8 is immunogenic in patients with disseminated gonococcal and meningococcal infections
108. Molecular characterization of FrpB, the 70-kilodalton iron-regulated outer membrane protein of Neisseria meningitidis
109. Analysis of the human Ig isotype response to lactoferrin binding protein A from Neisseria meningitidis
110. Response of Neisseria meningitidis to iron limitation
111. Coordination of iron by the ferric iron-binding protein of pathogenic Neisseria is homologous to the transferrins
112. For discussion: Live attenuated vaccines for group B meningococcus
113. Meningitis bacterium is viable without endotoxin
114. Antibody response in group B meningococcal disease determined by enzyme-linked immunosorbent assay with serotype 15 outer membrane antigen
115. Antibodies to meningococci in children with meningococcal disease
116. IgG subclass antibodies to serogroup B meningococcal outer membrane antigens following infection and vaccination
117. Antibody responses to serogroup B meningococcal outer membrane antigens after vaccination and infection
118. Humoral immune responses to Neisseria meningitidis in children
119. Meningococcal bacteremia: Clinical and serologic studies of infants with mild illness
120. The influence of active normal serum (complement) upon meningococci
121. Host defense against Neisseria meningitidis requires a complement-dependent bactericidal activity
122. Complement deficiency and antibody profile in survivors of meningococcal meningitis due to common serogroups in Italy
123. Complement deficiency states and infection: Epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency
124. Neisseria meningitidis and Neisseria gonorrhoeae bacteremia associated with C6, C7, or C8 deficiency
125. Complement deficiencies in patients over ten years old with meningococcal disease due to uncommon serogroups
126. Complement factor 9 deficiency in the serum of neonates
127. Complement deficiencies and meningococcal disease
128. Recognition and control of neisserial infection by antibody and complement
129. Sialic acid of group B Neisseria meningitidis regulates alternative complement pathway activation
130. Contribution of genes from the capsule gene complex (cps) to lipooligosaccharide biosynthesis and serum resistance in Neisseria meningitidis
131. Blocking of bactericidal killing of Neisseria meningitidis by antibodies directed against class 4 outer membrane protein
132. Mechanism of action of blocking immunoglobulin G for Neisseria gonorrhoeae
133. Association of low levels of mannan binding protein with a common defect of opsonisation
134. Increased frequency of homozygosity of abnormal mannan-binding-protein alleles in patients with suspected immunodeficiency
135. Mannose-binding lectin: The pluripotent molecule of the innate immune system
136. Familiar deficiency of mannose-binding lectin predisposing to meningococcal disease
137. A low serum concentration of mannan-binding protein is not associated with serogroup B or C meningococcal disease
138. Isolation and characterization of a mannan-binding protein from rabbit liver
139. Serum lectin with known structure activates complement through the classical pathway
140. A second serine protease associated with mannan-binding lectin that activates complement
141. Activation of the classical complement pathway by mannose-binding protein in association with a novel C1s-like serine protease
142. A serum lectin (mannan-binding protein) has complement-dependent bactericidal activity
143. The human mannose-binding protein functions as an opsonin
144. The effect of mannan-binding lectin on opsonophagocytosis of Neisseria meningitidis
145. Association of mutations in mannose binding protein gene with childhood infection in consecutive hospital series
146. Mannose binding protein gene mutations associated with unusual and severe infections in adults
147. Activation of complement by mannose-binding lectin on isogenic mutants of Neisseria meningitidis serogroup B
148. Pathogenic events during infection of the human nasopharynx with Neisseria meningitidis and Haemophilus influenzae
149. Meningococcal Opa and Opc proteins: Their role in colonization and invasion of human epithelial and endothelial cells
150. Adherence and hydrophobicity in Neisseria meningitidis and their relationship with surface charge
151. The effect of cigarette smoke on adherence of respiratory pathogens to buccal epithelial cells
152. Effect of smoking on meningococcal carriage
153. Host cell invasion by pathogenic Neisseriae
154. Resistance of normal serum IgA and secretory IgA to bacterial IgA proteases: Evidence for the presence of enzyme-neutralizing antibodies in both serum and secretory IgA, and also in serum IgG
155. Mechanisms of host immunity
156. Anti-alpha-galactosyl immunoglobulin A (IgA), IgG, and IgM in human secretions
157. Humoral immune response patterns of human mucosae: Induction and relation to bacterial respiratory tract infections
158. Inhibitory effect of saliva from secretors and non-secretors on binding of meningococci to epithelial cells
159. Secretor status and humoral immune responses to Neisseria lactamica and Neisseria meningitidis
160. Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans
161. Safety and immunogenicity testing of an intranasal group B meningococcal native outer membrane vesicle vaccine in healthy volunteers
162. Bactericidal antibody after colonization with Neisseria meningitidis
163. Crossed immunoelectrophoretic analysis of Neisseria meningitidis antigens and of corresponding antibodies in patients with meningococcal disease
164. Outer membrane antigens of Neisseria meningitidis group B serotype 2 studied by crossed immunoelectrophoresis
165. Cross-reactions between Neisseria meningitidis and twenty-seven other bacterial species
166. Cross-reacting serum opsonins in patients with meningococcal disease
167. Cross-antigenicity and immunogenicity between capsular polysaccharides of group C Neisseria meningitidis and of Escherichia coli K92
168. Antigenic relationship between Escherichia coli and Neisseria meningitidis
169. Immunochemical similarity between polysaccharide antigens of Escherichia coli 07: K1(L):NM and group B Neisseria meningitidis
170. Lactose fermenting organisms resembling Neisseria meningitidis
171. Current status of lactose-fermenting Neisseria
172. Neisseria lactamica as a vaccine against meningococcal disease
173. Antibody-dependent mononuclear cell-mediated antimeningococcal activity. Comparison of the effects of convalescent and postimmunization immunoglobulins G, M, and A
174. The interaction in vitro between group B meningococci and rabbit polymorphonuclear leukocytes. Demonstration of type specific opsonins and bactericidins
175. Ultrastructural studies on the fate of group B meningococci in human peripheral blood leukocytes
176. Egestion of degraded meningococci by polymorphonuclear leukocytes
177. Human IgG Fc receptor heterogeneity: Molecular aspects and clinical implications
178. Fc gamma receptor IIa (CD32) polymorphism in fulminant meningococcal septic shock in children
179. Killing of Neisseria meningitidis by human neutrophils: Implications for normal and complement-deficient individuals
180. Biochemical, structural, and functional abnormalities of polymorphonuclear leukocytes in the neonate
181. Nonopsonic phagocytosis of group C Neisseria meningitidis by human neutrophils
182. Phenotypic variants of meningococci and their potential in phagocytic interactions: The influence of opacity proteins, pili, PilC and surface sialic acids
183. The N-domain of the human CD66a adhesion molecule is a target for Opa proteins of Neisseria meningitidis and Neisseria gonorrhoeae
184. Neutrophil response to Neisseria meningitidis: Inhibition of adhesion molecule expression and phagocytosis by recombinant bactericidal/permeability-increasing protein (rBPI21)
185. Studies of human cord blood dendritic cells: Evidence for functional immaturity
186. Postnatal maturation of immune competence during infancy and childhood
187. Analysis of T helper and antigen-presenting cell functions in cord blood and peripheral blood leukocytes from healthy children of different ages
188. Neonatal tolerance revisited: Turning on newborn T cells with dendritic cells
189. Defective regional immunity in the respiratory tract of neonates is attributable to hyporesponsiveness of local dendritic cells to activation signals
190. Decreased mononuclear and polymorphonuclear chemotaxis in human newborns, infants, and young children
191. Immunobiology of childhood tuberculosis: A window on the ontogeny of cellular immunity
192. Defective production of interleukin-6 in very small premature infants in response to bacterial pathogens
193. Production of lymphotoxin and tumor necrosis factor by human neonatal mononuclear cells
194. Impaired production of gamma-interferon by newborn cells in vitro is due to a functionally immature macrophage
195. Phagocytosis-associated functions in neonatal monocyte-derived macrophages
196. Distinct role of neonatal and adult monocytes in the regulation of the in vitro antigen-induced plaque-forming cell response in man
197. IgA-dependent, monocyte-mediated, antibacterial activity
198. Antibody dependent cell mediated antibacterial activity of human mononuclear cells. I, K lymphocytes and monocytes are effective against meningococci in cooperation with human sera
199. Antibody-dependent cell-mediated antibacterial activity of human mononuclear cells. II. Immune specificity of antimeningococcal activity
200. Restoration of T cell-independent type 2 induction of Ig secretion by neonatal B cells in vitro
201. The role of soluble factors in T-B cell collaboration
202. T cell independent antigens
203. T cell-independent antigens type 2
204. Cellular immunity in patients with meningococcal disease and in vaccinated subjects
205. Bacterial lipoproteins may substitute for cytokines in the humoral immune response to T cell-independent type II antigens
206. Neisserial porins may provide critical second signals to polysaccharide-activated murine B cells for induction of immunoglobulin secretion
207. T-cell modulation of the antibody response to bacterial polysaccharide antigens
208. T-cell modulation of the murine antibody response to Neisseria meningitidis group A capsular polysaccharide
209. Regulation of the antibody response to pneumococcal polysaccharide by thymus-derived cells
210. Characteristics of amplifier T cells involved in the antibody response to the capsular polysaccharide of type III Streptococcus pneumoniae
211. Immune Response of human infants of polysaccharide vaccines of group A and C Neisseria meningitidis
212. Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine
213. Immune response to revaccination with meningococcal A and C polysaccharides in Gambian children following repeated immunisation during early childhood
214. Immunogenicity of meningococcal polysaccharides in man
215. Meningococcal serogroup C conjugate vaccination in infancy induces persistent immunological memory
216. T-cell responses to outer membrane proteins of Neisseria meningitidis: Comparative study of the Opa, Opc, and PorA proteins
217. Human B- and T-cell responses after immunization with a hexavalent PorA meningococcal outer membrane vesicle vaccine
218. Human T-cell responses after vaccination with the Norwegian group B meningococcal outer membrane vesicle vaccine
219. Cellular immune responses to Neisseria meningitidis in children
220. Comparative sequence analysis of the class 1 protein gene (porA) from three strains of Neisseria meningitidis: Synthetic peptides define the epitopes responsible for serosubtype specificity
221. T cell recognition of Neisseria meningitidis class 1 outer membrane proteins. Identification of T cell epitopes with selected synthetic peptides and determination of HLA restriction elements
222. Identification of T cell epitopes occurring in a meningococcal class 1 outer membrane protein using overlapping peptides assembled with simultaneous multiple peptide synthesis
223. Microheterogeneity in the recognition of a HLA-DR2-restricted T cell epitope from a meningococcal outer membrane protein
224. Murine cross-reactive T-cell epitopes of Neisseria meningitidis outer membrane proteins
225. Polyclonal activation of human peripheral blood lymphocytes by bacterial porins and defined porin fragments
226. Polyclonal activation of murine B lymphocytes in vitro by Salmonella typhimurium porins
227. Neisserial porins induce B lymphocytes to express costimulatory B7-2 molecules and to proliferate
228. Immunogenicity of a Haemophilus influenzae polysaccharide-Neisseria meningitidis outer membrane protein complex conjugate vaccine
229. Infection associated with asplenia: Risks, mechanisms, and prevention
230. Complications of splenectomy. Etiology, prevention and management
231. Antibody responses to polysaccharide and polysaccharide-conjugate vaccines after treatment of Hodgkin disease
232. Congenital asplenia: Immunologic assessment and a clinical review of eight surviving patients
233. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis
234. Sialylation and human neutrophil killing of group C Neisseria meningitidis
235. Meningococcal molecular mimicry and the search for an ideal vaccine
236. Lipooligosaccharides (LOS) of Neisseria gonorrhoeae and Neisseria meningitidis have components that are immunochemically similar to precursors of human blood group antigens. Carbohydrate sequence specificity of the mouse monoclonal antibodies that recognize crossreacting antigens on LOS and human erythrocytes
237. Attachment of Neisseria meningitidis to human mucosal surfaces: Influence of pili and type of receptor cell
238. Isolation of Neisseria meningitidis mutants deficient in class 1 (porA) and class 3 (porB) outer membrane proteins
239. An outer membrane protein of Neisseria meningitidis group B responsible for serotype specificity
240. Expression of the Opc protein correlates with invasion of epithelial and endothelial cells by Neisseria meningitidis
241. Identification of two major families of transferrin receptors among Neisseria meningitidis strains based on antigenic and genomic features
242. Comparative analysis of the transferrin and lactoferrin binding proteins in the family Neisseriaceae
243. Sequence variability of FrpB, a major iron-regulated outer-membrane protein in the pathogenic Neisseriae
244. Ferric enterobactin binding and utilization by Neisseria gonorrhoeae
245. Vaccine potential of meningococcal FrpB: Studies on surface exposure and functional attributes of common epitopes
246. Purification and characterization of the major iron-regulated protein expressed by pathogenic Neisseriae
247. Bactericidal activity of antibodies elicited against the Neisseria meningitidis 37-kDa ferric binding protein (FbpA) with different adjuvants